ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
카텝신 억제제 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년에는 12억 6,000만 달러에 달할 것으로 예상되며, CAGR 10.8%로 성장할 것으로 예상됩니다. 예측 기간의 성장은 표적 치료제 개발, 신경퇴행성 질환 치료법 증가, 연구개발 자금 증가, 정밀의료에 대한 수요 증가, 감염성 질환 치료에 대한 적용 확대 등에 기인할 것으로 보입니다. 이 기간의 주요 동향으로는 선택적 카텝신 억제제의 부상, 생명공학 기업 간 제휴, 경구제 중심, AI의 신약개발 활용, 희귀질환 치료제로의 확대 등을 꼽을 수 있습니다.
신경 퇴행성 질환의 발병률 증가는 카텝신 억제제 시장의 성장을 촉진할 것으로 예상됩니다. 신경퇴행성 질환은 중추신경계의 신경세포가 점차적으로 퇴화 또는 사멸하는 것이 특징이며, 특히 뇌에 영향을 미치는 진행성, 종종 돌이킬 수 없는 질환입니다. 이러한 질병의 증가는 고령화 사회와 밀접한 관계가 있습니다. 평균 수명이 연장됨에 따라 알츠하이머병, 파킨슨병과 같은 질병이 더욱 보편화되어 의료 시스템에 더 많은 부담을 주고 있습니다. 카텝신 억제제는 아밀로이드 베타(AB) 생성 및 신경 염증을 조절하는 능력으로 인해 신경 퇴행성 질환의 잠재적 치료제로 연구되고 있습니다. 예를 들어, Alzheimer's Association에 따르면, 2024년 65세 이상 미국인 중 약 690만 명이 알츠하이머형 치매를 앓고 있으며, 2060년까지 이 숫자는 거의 두 배인 1,380만 명으로 증가할 것으로 예상됩니다. 결과적으로 신경퇴행성 질환의 유병률 증가가 카텝신 억제제 수요를 견인하고 있습니다.
카텝신 억제제 시장의 기업들은 신약 개발의 혁신을 촉진하고, 제품 포트폴리오를 확장하며, 시장 진입을 가속화하기 위해 전략적 파트너십을 체결하고 있습니다. 이러한 파트너십은 상호보완적인 전문 지식과 자원을 활용하여 임상시험 및 허가 성공률을 높이는 것을 목표로 합니다. 예를 들어, 2024년 6월 일본 소재 신약개발 기업 Alivexis는 스위스 소재 생명공학 기업 Melodia Therapeutics와 독점 라이선스 계약을 체결한 바 있습니다. 이번 계약은 Alivexis의 MOD-A 탐색 프로그램에서 발굴된 신규 카텝신 C 억제제 MDI-0151의 개발, 제조 및 상업화에 대한 전 세계 권리를 부여하는 것으로, MDI-0151은 ANCA 관련 혈관염과 같은 호중구 중심의 염증성 질환을 타겟으로 합니다. Melodia는 임상적 개념증명을 확립하기 위한 1/2a상 시험을 위해 IND 획득을 위한 활동을 시작할 예정입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 카텝신 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
최종 이용 산업 분석
세계의 카텝신 억제제 시장 : 성장률 분석
세계의 카텝신 억제제 시장 실적 : 규모와 성장, 2019-2024년
세계의 카텝신 억제제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 카텝신 억제제 전체 시장(TAM)
제6장 시장 세분화
세계의 카텝신 억제제 시장 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
저분자 억제제
펩타이드 억제제
단클론항체
세계의 카텝신 억제제 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
암 치료
자가면역질환
염증성 질환
신경변성질환
기타
세계의 카텝신 억제제 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
온라인 약국
소매 약국
병원·클리닉
세계의 카텝신 억제제 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제약회사
학술연구기관
계약 연구기관(CRO)
세계의 카텝신 억제제 시장 : 저분자 억제제 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
가역적 억제제
비가역적 억제제
합성 화합물
천연물 유래 억제제
세계의 카텝신 억제제 시장 : 펩타이드 억제제 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
직쇄 펩타이드
환형 펩타이드
변성 펩타이드
펩타이드 모방약
세계의 카텝신 억제제 시장 : 단클론항체 하위 세분화 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
인간화 단클론항체
완전 인간 단클론항체
키메라 단클론항체
이중특이성항체
제7장 지역별·국가별 분석
세계의 카텝신 억제제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 카텝신 억제제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
카텝신 억제제 시장 : 경쟁 구도
카텝신 억제제 시장 : 기업 개요
Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
Bio-Techne Corporation Overview, Products and Services, Strategy and Financial Analysis
AddLife AB Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
BioVision
R&D Systems Inc.
Cayman Chemical
Selleck Chemicals
Santa Cruz Animal Health
Tocris Bioscience
Virobay Inc.
MedChemExpress
BOC Sciences
Biorbyt Ltd
GlpBio Technology
Echelon Biosciences
AG Scientific
ApexBio Technology
OXiGENE Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
카텝신 억제제 시장 2029년 : 새로운 기회를 제공하는 국가
카텝신 억제제 시장 2029년 : 새로운 기회를 제공하는 부문
카텝신 억제제 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Cathepsin inhibitors are compounds that block the activity of cathepsins, enzymes involved in various biological processes such as protein degradation and cell regulation. These inhibitors are being studied for their potential to treat diseases by modulating cathepsin activity. Their ability to target specific biological mechanisms positions them as promising candidates for therapeutic development.
The main types of cathepsin inhibitors include small molecule inhibitors, peptide inhibitors, and monoclonal antibodies. Small molecule cathepsin inhibitors are low molecular weight compounds specifically designed to block the activity of cathepsin enzymes. These inhibitors are applied in the treatment of cancer, autoimmune diseases, inflammatory disorders, neurodegenerative conditions, and other therapeutic areas. Distribution channels for these products include online pharmacies, retail pharmacies, and hospitals and clinics, serving end users such as pharmaceutical companies, academic and research institutions, and contract research organizations (CROs).
The cathepsin inhibitor market research report is one of a series of new reports from The Business Research Company that provides cathepsin inhibitor market statistics, including cathepsin inhibitor industry global market size, regional shares, competitors with a cathepsin inhibitor market share, detailed cathepsin inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the cathepsin inhibitor industry. This cathepsin inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cathepsin inhibitor market size has grown rapidly in recent years. It will grow from$0.76 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth during the historic period can be attributed to the rising incidence of cancer, the increasing prevalence of inflammatory diseases, growing investments in drug discovery, advancements in protease research, and the expanding use of cathepsin inhibitors in treating bone disorders.
The cathepsin inhibitor market size is expected to see rapid growth in the next few years. It will grow to$1.26 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to the development of targeted therapies, the rise in treatments for neurodegenerative diseases, increased funding for research and development, growing demand for precision medicine, and expanding applications in infectious disease treatment. Key trends during this period include the emergence of selective cathepsin inhibitors, collaborations between biotech firms, a focus on oral drug formulations, the use of AI in drug discovery, and the expansion into therapeutics for rare diseases.
The growing incidence of neurodegenerative disorders is expected to fuel the expansion of the cathepsin inhibitor market. Neurodegenerative disorders are progressive, often irreversible conditions characterized by the gradual deterioration or death of neurons in the central nervous system, particularly impacting the brain. The rise in these disorders is closely linked to the aging population. As life expectancy increases, conditions such as Alzheimer's and Parkinson's become more common, adding further strain to healthcare systems. Cathepsin inhibitors are being studied as potential therapeutic agents for neurodegenerative diseases due to their ability to modulate amyloid-beta (AB) production and neuroinflammation. For example, according to the Alzheimer's Association, in 2024, about 6.9 million Americans aged 65 and older are living with Alzheimer's dementia, and this number is expected to nearly double to 13.8 million by 2060. As a result, the increasing prevalence of neurodegenerative disorders is driving the demand for cathepsin inhibitors.
Companies in the cathepsin inhibitor market are forming strategic partnerships to drive innovation in drug discovery, expand their product portfolios, and speed up market entry. These collaborations aim to leverage complementary expertise and resources to enhance the success rates of clinical trials and regulatory approvals. For example, in June 2024, Alivexis, a Japan-based drug discovery company, entered into an exclusive licensing agreement with Melodia Therapeutics, a Switzerland-based biotech firm. The agreement grants worldwide rights to the development, manufacturing, and commercialization of MDI-0151, a novel cathepsin C inhibitor. MDI-0151, identified in Alivexis' MOD-A discovery program, is targeted at neutrophil-driven inflammatory diseases such as ANCA-associated vasculitis. Melodia plans to initiate IND-enabling activities in preparation for Phase 1/2a studies to establish clinical proof of concept.
In April 2022, AddLife AB, a Swedish life science company, acquired BioCat GmbH for an undisclosed amount. This acquisition was aimed at strengthening AddLife's presence in the DACH (Germany, Austria, and Switzerland) region and expanding its Labtech business area through increased collaboration with its existing European subsidiaries. BioCat GmbH, a Germany-based life sciences company, specializes in providing cathepsin K inhibitors for use in biological research and drug development.
Major players in the cathepsin inhibitor market are Merck KGaA, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Bio-Techne Corporation, AddLife AB, BioVision, R&D Systems Inc., Cayman Chemical, Selleck Chemicals, Santa Cruz Animal Health, Tocris Bioscience, Virobay Inc., MedChemExpress, BOC Sciences, Biorbyt Ltd, GlpBio Technology, Echelon Biosciences, AG Scientific, ApexBio Technology, and OXiGENE Inc.
North America was the largest region in the cathepsin Inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cathepsin inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cathepsin inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cathepsin inhibitor market consists of sales of small-molecule inhibitors, prescription drugs, research-grade inhibitors, and therapeutic formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cathepsin Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cathepsin inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cathepsin inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cathepsin inhibitor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Small Molecule Inhibitors; Peptide Inhibitors; Monoclonal Antibodies
2) By Application: Cancer Treatment; Autoimmune Diseases; Inflammatory Diseases; Neurodegenerative Disorders; Other Therapeutic Areas
3) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Hospitals And Clinics
4) By End User: Pharmaceutical Companies; Academic And Research Institutes; Contract Research Organizations (CROs)
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Cathepsin Inhibitor Market Characteristics
3. Cathepsin Inhibitor Market Trends And Strategies
4. Cathepsin Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Cathepsin Inhibitor Growth Analysis And Strategic Analysis Framework
5.1. Global Cathepsin Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cathepsin Inhibitor Market Growth Rate Analysis
5.4. Global Cathepsin Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cathepsin Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cathepsin Inhibitor Total Addressable Market (TAM)
6. Cathepsin Inhibitor Market Segmentation
6.1. Global Cathepsin Inhibitor Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Inhibitors
Peptide Inhibitors
Monoclonal Antibodies
6.2. Global Cathepsin Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Treatment
Autoimmune Diseases
Inflammatory Diseases
Neurodegenerative Disorders
Other Therapeutic Areas
6.3. Global Cathepsin Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online Pharmacies
Retail Pharmacies
Hospitals And Clinics
6.4. Global Cathepsin Inhibitor Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Academic And Research Institutes
Contract Research Organizations (CROs)
6.5. Global Cathepsin Inhibitor Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Reversible Inhibitors
Irreversible Inhibitors
Synthetic Compounds
Natural Product-Derived Inhibitors
6.6. Global Cathepsin Inhibitor Market, Sub-Segmentation Of Peptide Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Linear Peptides
Cyclic Peptides
Modified Peptides
Peptidomimetics
6.7. Global Cathepsin Inhibitor Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Humanized Monoclonal Antibodies
Fully Human Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Bispecific Antibodies
7. Cathepsin Inhibitor Market Regional And Country Analysis
7.1. Global Cathepsin Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cathepsin Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
